Patritumab Deruxtecan Biologics License Application for Patients With Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

Why did Trump double steel and aluminum tariffs? How are tariffs impacting US retailers’ profits? What caused $14B in EV and renewable projects cancellation? Why is JPMorgan dimon warning about bond market cracks? How did Tesla's robotaxi rollout alarm the public? Why is the EU threatening countermeasures after US tariffs? What’s behind Meta’s plan to replace humans with AI?

Patritumab Deruxtecan Biologics License Application for Patients With Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

merck.com/news/patritumab-deruxtecan-biologics-license-application-for-patients-with-previously-treated-locally-advanced-or-metastatic-egfr-mutated-non-small-cell-lung-cancer-voluntarily-withdrawn

Patritumab Deruxtecan Biologics License Application for Patients With Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
May 29, 2025 7:00 am ET
BASKING RIDGE, N.J. & RAHWAY, N.J., May 29, 2025 – The Biologics License…

This story appeared on merck.com, 2025-05-29 14:08:50.959000.